Myriad Genetics 향후 성장

Future 기준 점검 0/6

Myriad Genetics (는) 각각 연간 67.9% 및 4.4% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 69.4% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 0.9% 로 예상됩니다.

핵심 정보

67.9%

이익 성장률

69.39%

EPS 성장률

Biotechs 이익 성장	23.0%
매출 성장률	4.4%
향후 자기자본이익률	0.87%
애널리스트 커버리지	Good
마지막 업데이트	15 Dec 2025

최근 향후 성장 업데이트

Recent updates

Estimating The Intrinsic Value Of Myriad Genetics, Inc. (NASDAQ:MYGN)

Sep 30

Myriad Genetics, Inc. (NASDAQ:MYGN) Held Back By Insufficient Growth Even After Shares Climb 28%

Aug 17

Myriad: HCT In Oncology Continues To Deliver Increased Volume And Revenue Growth

Aug 06

Myriad Genetics, Inc. (NASDAQ:MYGN) Stock Catapults 29% Though Its Price And Business Still Lag The Industry

Jun 25

Lacklustre Performance Is Driving Myriad Genetics, Inc.'s (NASDAQ:MYGN) 48% Price Drop

May 09

PATHOMIQ AI Partnership Will Expand Oncology And Women's Health

Mar 24 Strategic partnerships and investments in AI and women's health aim to enhance oncology offerings and capture larger market shares, driving revenue growth.

Myriad Genetics, Inc. (NASDAQ:MYGN) Not Doing Enough For Some Investors As Its Shares Slump 31%

Mar 16

Here's What Analysts Are Forecasting For Myriad Genetics, Inc. (NASDAQ:MYGN) After Its Yearly Results

Feb 26

Myriad Genetics: Navigating Through A Setback

Jan 16

An Intrinsic Calculation For Myriad Genetics, Inc. (NASDAQ:MYGN) Suggests It's 45% Undervalued

Jan 08

Myriad Genetics, Inc. (NASDAQ:MYGN) Just Reported Earnings, And Analysts Cut Their Target Price

Nov 13

Is Myriad Genetics (NASDAQ:MYGN) A Risky Investment?

Nov 02

Why Investors Shouldn't Be Surprised By Myriad Genetics, Inc.'s (NASDAQ:MYGN) 33% Share Price Plunge

Nov 02

Myriad Genetics, Inc.'s (NASDAQ:MYGN) Price Is Right But Growth Is Lacking After Shares Rocket 26%

May 11

Analysts Have Made A Financial Statement On Myriad Genetics, Inc.'s (NASDAQ:MYGN) First-Quarter Report

May 09

Does Myriad Genetics (NASDAQ:MYGN) Have A Healthy Balance Sheet?

Mar 28

이익 및 매출 성장 예측

NasdaqGS:MYGN - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
12/31/2028	943	-56	N/A	N/A	4
12/31/2027	915	-53	11	35	9
12/31/2026	867	-66	-4	25	12
12/31/2025	822	-379	-31	-14	12
9/30/2025	825	-400	-29	-2	N/A
6/30/2025	833	-395	-50	-23	N/A
3/31/2025	831	-101	-36	-6	N/A
12/31/2024	838	-127	-38	-9	N/A
9/30/2024	824	-116	-107	-70	N/A
6/30/2024	802	-155	-141	-93	N/A
3/31/2024	774	-235	-155	-96	N/A
12/31/2023	753	-263	-184	-111	N/A
9/30/2023	734	-274	-138	-63	N/A
6/30/2023	699	-248	-119	-44	N/A
3/31/2023	695	-146	-155	-93	N/A
12/31/2022	678	-112	-152	-106	N/A
9/30/2022	661	-77	-143	-108	N/A
6/30/2022	672	-18	-164	-145	N/A
3/31/2022	682	-8	-117	-100	N/A
12/31/2021	691	-27	1	19	N/A
9/30/2021	684	-57	-7	14	N/A
6/30/2021	662	-97	-26	-6	N/A
3/31/2021	566	-148	11	28	N/A
12/31/2020	557	-224	-40	-27	N/A
9/30/2020	598	-194	-25	-14	N/A
6/30/2020	639	-199	51	61	N/A
3/31/2020	761	-148	53	62	N/A
12/31/2019	813	-26	43	52	N/A
9/30/2019	835	-15	83	92	N/A
6/30/2019	851	5	N/A	84	N/A
3/31/2019	830	23	N/A	100	N/A
12/31/2018	796	26	N/A	105	N/A
9/30/2018	767	54	N/A	100	N/A
6/30/2018	744	133	N/A	116	N/A
3/31/2018	749	130	N/A	105	N/A
12/31/2017	763	126	N/A	134	N/A
9/30/2017	771	101	N/A	133	N/A
6/30/2017	729	17	N/A	106	N/A
3/31/2017	757	32	N/A	108	N/A
12/31/2016	751	63	N/A	113	N/A
9/30/2016	748	94	N/A	134	N/A
6/30/2016	741	117	N/A	166	N/A
3/31/2016	757	121	N/A	179	N/A
12/31/2015	747	108	N/A	163	N/A
9/30/2015	738	95	N/A	163	N/A
6/30/2015	723	80	N/A	141	N/A
3/31/2015	722	95	N/A	130	N/A

애널리스트 향후 성장 전망

수입 대 저축률: MYGN 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: MYGN 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: MYGN 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: MYGN 의 수익(연간 4.4%)이 US 시장(연간 10.4%)보다 느리게 성장할 것으로 예상됩니다.

고성장 매출: MYGN 의 수익(연간 4.4%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: MYGN의 자본 수익률은 3년 후 0.9%로 낮을 것으로 예상됩니다.

성장 기업 찾아보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2026/01/03 00:03
종가	2026/01/02 00:00
수익	2025/09/30
연간 수익	2024/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 Github 페이지에서 확인할 수 있으며, 보고서 활용 방법에 대한 가이드와 Youtube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Myriad Genetics, Inc.는 37명의 분석가가 다루고 있습니다. 이 중 12명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Jack Meehan	Barclays
Derek Taller	Benchmark Company
Michael Ryskin	BofA Global Research

Myriad Genetics 향후 성장

Future 기준 점검 0/6

핵심 정보

최근 향후 성장 업데이트

Price target increased by 8.5% to US$8.52

Myriad Genetics, Inc. Reiterates Earnings Guidance for the Full-Year 2025

Consensus EPS estimates fall by 507%, revenue upgraded

Myriad Genetics, Inc. Revises Financial Guidance for the Full Year of 2025

Price target decreased by 9.0% to US$9.00

Consensus EPS estimates upgraded to US$0.56 loss, revenue downgraded

Recent updates

Price target increased by 8.5% to US$8.52

Myriad Genetics Adds 15 Clinically Actionable Genes to MyRisk®? Hereditary Cancer Test to Support Evolving Clinical Needs

Myriad Genetics to Highlight Genetic Testing Advancements at 2025 National Society of Genetic Counselors Annual Conference

Third quarter 2025 earnings: EPS misses analyst expectations

Now 37% undervalued

Myriad Genetics, Inc. Reiterates Earnings Guidance for the Full-Year 2025

Myriad Genetics, Inc. Announces A Post-Hoc Analysis of the Precision Medicine in Mental Health Care Study

Myriad Genetics, Inc. to Report Q3, 2025 Results on Nov 03, 2025

Myriad Genetics, Inc. Adds F8, FXN Genes to Foresight Universal Plus Panel

Myriad Genetics, Inc. Announces Executive Changes, Effective October 24, 2025

Estimating The Intrinsic Value Of Myriad Genetics, Inc. (NASDAQ:MYGN)

Myriad Genetics, Inc. Announces Precise MRD Clinical Data Published in The Lancet Oncology

Myriad Genetics, Inc. Announces the Publication of New Meta- Analysis of Six Prospective Controlled Studies

Myriad Genetics, Inc. Announces Chief Financial Officer Changes

Myriad Genetics, Inc. (NASDAQ:MYGN) Held Back By Insufficient Growth Even After Shares Climb 28%

New Myriad Genetics, Inc. Releases Findings from Its Latest Cancer Risk Survey

Consensus EPS estimates fall by 507%, revenue upgraded

Second quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Myriad: HCT In Oncology Continues To Deliver Increased Volume And Revenue Growth

Myriad Genetics, Inc. Revises Financial Guidance for the Full Year of 2025

Myriad Genetics, Inc. to Report Q2, 2025 Results on Aug 05, 2025

Myriad Genetics, Inc. (NASDAQ:MYGN) Stock Catapults 29% Though Its Price And Business Still Lag The Industry

Myriad Genetics, Inc. Announces Early Access to the FirstGene Multiple Prenatal Screen

Myriad Genetics Shares New Clinical Data Demonstrating Sensitivity of Precise Mrd Across Multiple Cancer Types

Price target decreased by 9.0% to US$9.00

Consensus EPS estimates upgraded to US$0.56 loss, revenue downgraded

Lacklustre Performance Is Driving Myriad Genetics, Inc.'s (NASDAQ:MYGN) 48% Price Drop

Myriad Genetics, Inc. Announces Riskscore Study Published in JCO Precision Oncology

First quarter 2025 earnings released: US$0.001 loss per share (vs US$0.29 loss in 1Q 2024)

Myriad Genetics, Inc. Updates Earnings Guidance for the Year 2025

Myriad Genetics, Inc. to Report Q1, 2025 Results on May 06, 2025

Myriad Genetics Highlights MRD Clinical Validity Data At American Association for Cancer Research Annual Meeting

Myriad Genetics, Inc. Announces Study Results Show Patients with Depression had Fewer Psychiatric Hospitalizations After GeneSight Testing

Price target decreased by 9.9% to US$16.01

Myriad Genetics, Inc., Annual General Meeting, Jun 05, 2025

Price target decreased by 7.3% to US$16.69

Myriad Genetics, Inc. Appoints Brian Donnelly as Chief Commercial Officer, Effective May 1, 2025

PATHOMIQ AI Partnership Will Expand Oncology And Women's Health

Myriad Genetics, Inc. (NASDAQ:MYGN) Not Doing Enough For Some Investors As Its Shares Slump 31%

Consensus EPS estimates fall by 11%

Consensus EPS estimates fall by 11%

Myriad Genetics, Inc. Announces Chief Executive Officer Changes

Here's What Analysts Are Forecasting For Myriad Genetics, Inc. (NASDAQ:MYGN) After Its Yearly Results

Myriad Genetics, Inc. Announces Management Changes

Full year 2024 earnings released

Price target decreased by 8.6% to US$19.41

Myriad Genetics, Inc. to Report Q4, 2024 Results on Feb 24, 2025

Price target decreased by 8.0% to US$19.54

Consensus EPS estimates fall by 11%

Myriad Genetics: Navigating Through A Setback

Myriad Genetics, Inc. Provides Unaudited Earnings Guidance for the Fourth Quarter and Full-Year Ended December 31, 2024 and Full-Year of 2025

An Intrinsic Calculation For Myriad Genetics, Inc. (NASDAQ:MYGN) Suggests It's 45% Undervalued

Price target decreased by 10% to US$21.40

Myriad Genetics Elects Mark S. Davis as New Board Member

Myriad Genetics, Inc. (NASDAQ:MYGN) Just Reported Earnings, And Analysts Cut Their Target Price

Price target decreased by 11% to US$26.69

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Myriad Genetics, Inc. Reports Impairment Charges for the Third Quarter Ended September 30, 2024

Is Myriad Genetics (NASDAQ:MYGN) A Risky Investment?

Why Investors Shouldn't Be Surprised By Myriad Genetics, Inc.'s (NASDAQ:MYGN) 33% Share Price Plunge

Myriad Genetics, Inc. to Report Q3, 2024 Results on Nov 07, 2024

CEO, President & Director notifies of intention to sell stock

Now 21% undervalued after recent price drop

Myriad Genetics, Inc. Provides Earnings Guidance for the Third Quarter 2024 and Reaffirms Earnings Guidance for the Full-Year 2024

Is Myriad Genetics, Inc. (NASDAQ:MYGN) Trading At A 31% Discount?

Myriad Genetics, Inc. to Share New Data Highlighting Genetic Testing Advancements at 2024 National Society of Genetic Counselors Annual Conference

Independent Director recently sold US$271k worth of stock

Independent Director notifies of intention to sell stock

Myriad Genetics, Inc.'s (NASDAQ:MYGN) Price Is Right But Growth Is Lacking